This week, the Coalition sent Congressional leadership a letter detailing the results of a recent survey about how underwater biosimilars are impacting physicians’ ability to provide high-quality care. Almost all of the nearly 200 practices queried reported being underwater on several biosimilars, with rituximab and infliximab biosimilars being the most common.
Advocates for Arthritis 2025: United for the Future of Rheumatology Care
In visits to Congress members and staff, more than 120 ACR/ARP members and patients urged action to improve patient access to quality treatment. The meetings included discussions about the importance of research funding, ensuring adequate Medicare reimbursement, protecting Medicaid, and making PBMs more transparent and accountable. It’s not too late to amplify their message.
ACR Leaders Discuss Rheumatology Medications at Medicare Drug Price Negotiation Town Hall
On April 30, Rebecca Shepherd, MD, MBA, and Amanda Myers, MD, represented rheumatology in a live town hall on the Medicare Drug Price Negotiation Program, describing the benefits of apremilast and nintedanib for patients with rheumatic disease.
Advocates for Arthritis 2025: Preview of Key Issues
When ACR volunteer leaders, members and patient advocates head to Capitol Hill in May, they will urge members of Congress to protect Medicare and Medicaid against cuts, restore research funding and reform pharmacy benefit managers for better transparency and accountability.
RheumPAC Matching Campaign Now Underway
The annual matching campaign will run through May, coinciding with the ACR’s Advocates for Arthritis event. If you have not made your 2025 donation yet, now is the best time to invest for the largest impact.
Colin Edgerton, MD, Testifies in Congressional Hearing on Biosimilars
In front of the U.S. House Ways and Means Subcommittee, Dr. Edgerton described how challenges of biosimilar costs threaten patient care and outlined several potential legislative solutions.
Calling Rheumatologist Leaders: AMA House of Delegates Opportunity
The ACR’s delegation to the American Medical Association House of Delegates is seeking ACR members who may be interested in serving as representatives to the Young Physician Section.
ACR Monitoring HHS Workforce Reductions, Function Consolidations
Changes announced April 1 will cut 10,000 positions at the U.S. Department of Health & Human Services and consolidate many department functions. The ACR is monitoring how these changes may impact regulatory issues of concern to ACR members.
Looking Ahead to Advocates for Arthritis 2025
This May, more than 120 ACR leaders, fellows and patients with rheumatic disease will converge in Washington, D.C., to lobby Congress on issues including protecting Medicare and Medicaid, National Institutes of Health research funding and pharmacy benefit manager reform.
State Legislative Update, Spring 2025
With the state legislative session in full swing, the ACR is currently tracking 114 pieces of state legislation across many issue areas, including utilization management, prescription drug review boards and vaccines.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 96
- Next Page »